Plymouth Pharmaceuticals, Inc. is a leading research and development company exploring safe, effective, oral therapies for inflammatory skin disorders.?Plymouth offers Rx and OTC products for psoriasis, eczema, acne and seborrhea dermatitis.
Cosmetic Specialty Labs is skilled in developing high end, prestige skin care products, as well as custom formulated over the counter drugs.
IPS Research Company provides phase 1-4 inpatient and outpatient clinical trials. IPS Research specializes in clinical drug trials dealing with psychiatric disorders, including Depression, Schizophrenia, Bipolar Depression, ADHD, GAD, PTSD, Dementia, Alzheimer?s Disease, Child Depression and a variety of Anxiety Disorders.
PreDENT has developed a vaccine to help prevent gingivitis and periodontal disease in pets?that produces significant pain and possibly even fatal damage to an animal?s organs.
Sensuli, LLC is developing a true once-a-day glucose-responsive insulin that may mimic a healthy human pancreas. Sensulin? may eliminate the need for basal & prandial insulin, offer a substantial improvement in the standard of care, and most importantly, give those with diabetes a chance at a normal life.
Anastasia Marie Labs, Inc. specializes in over-the-counter diabetic skin treatment products.
Selexys is a development stage biopharmaceutical company focused on the treatment of inflammatory and thrombotic diseases. ?The company has developed antibodies that block recruitment of white blood cells to activated endothelium and platelets. ?
Cytovance? Biologics adds significant value to biopharmaceutical development programs assisting companies to advance recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in international markets.
DermaMedics is a skin care company that specializies in the discovery of technologies for the dermatology market.
Otologic Pharmaceutics, Inc. is an organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balance health.
Choncept?s scientific innovation is focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.
Kemmx Corporation is a start-up, biotechnology company pioneering the development and commercialization of targeted analgesics for chronic pain. Their topical analgesic formulations provide long lasting pain relief with minimal side effects.
EpimedX, LLC is a biotechnology company that was founded in 2011 with the mission to develop Gene Regulation Therapy? ? a promising technology that is expected to provide a safe, cost-effective, and permanent treatment for sickle cell disease, beta-thalassemia, and malaria without dangerous or harmful side effects.
Arthrokinex is a comprehensive joint health program that can reduce or eliminate joint pain from osteoarthritis through the healing powers of the patient’s own blood without complications.
UltraBotanica has developed a patented method to bind curcumin to whey protein, effectively increasing the bioavailability by 15,000x.
Hyalose specializes in Hyaluronic Acid production and application. The Emergent Technologies Inc. ?Sugar Companies? offer innovative technologies for producing Hyaluronic Acid, heparosan, and chondroitin in a reproducible and safe manner for a variety of medical and aesthetic uses. Hyalose was formed to commercialize unique recombinant technologies for producing Hyaluronic Acid, an important biomolecule for many healthcare and cosmetic applications.
Wavetech, LLC is a privately held company specializing in research and development in emerging technology markets. Their emphasis is on electromagnetic technologies, including terahertz, artificial materials, and nondestructive evaluation.
DormaTarg, Inc is a biotechnology company researching and developing therapeutic drugs for cancer recurrence prevention.
Heparinex is a biotechnology company focused on the development of novel recombinant synthesis of heparinoid compounds for various markets including anticoagulation, biomaterials, and cellular modulation applications.
Synereca Pharmaceuticals addresses the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.